Talking Ketamine Podcast

For decades, neurology has viewed adult brain damage as a relatively permanent state, offering mostly compensatory therapies to help patients adapt to their deficits. But Episode 59 explores a 2026 systematic review by Leon-Rojas and Sacks-Zimmerman that flips the script: could subanesthetic ketamine actually act as a powerful cognitive enhancer? We unpack the paradox of using a dissociative anesthetic to sharpen the mind. The secret lies in looking past the acute intoxication phase—the temporary "construction zone"—to the structural remodeling that follows. We explore ketamine's two-phase neuroprotective mechanism: acting first as a "fire extinguisher" to block NMDA receptors and stop toxic glutamate floods (excitotoxicity), and second as "fertilizer" by releasing BDNF to sprout new neural bridges (synaptogenesis). While animal models show a staggering 93.2% success rate in restoring cognitive functions like working memory and spatial learning, the review's single human study on Huntington's disease showed short-term cognitive impairment. We discuss why timing and context are everything: to truly harness this drug, the biological "window of neuroplasticity" must be actively paired with rigorous, targeted neurorehabilitation to guide the brain's rewiring. Reference: Leon-Rojas, J. E., Mascialino, G., Vinueza Mera, L., Hinojosa-Figueroa, M. S., Navas Arias, C. F., Cadena Barberis, E. D., & Sacks-Zimmerman, A. (2026). Ketamine as a potential cognitive enhancer in neurological disorders: Evidence from preclinical and clinical studies. Frontiers in Neurology, 17, 1786249. https://doi.org/10.3389/fneur.2026.1786249

For decades, the clinical focus of treating Major Depressive Disorder has been on alleviating profound sadness. However, traditional monoaminergic antidepressants often fall short of treating anhedonia—the absolute absence of pleasure—and can even cause "emotional blunting" by placing an artificial ceiling on a patient's dopamine-driven joy. In Episode 58, we explore a landmark 2026 systematic review by Faisal and colleagues that synthesizes 13 neuroimaging studies to show how ketamine acts not just as an antidepressant, but as a "pro-joy intervention." We break down the brain's reward architecture into the "Engine" (primitive structures like the striatum and nucleus accumbens) and the "Steering Wheel" (the prefrontal cortex). Chronic depression causes the dendritic spines connecting these regions to wither, leaving the engine dead. But the neuroimaging data is staggering: functional MRI (fMRI) measuring the BOLD signal during the Monetary Incentive Delay task shows that ketamine rapidly reactivates the striatum's response to reward anticipation. We also dive into PET scan data, revealing how ketamine modulates the 5-HT1B serotonin receptor—acting like a "bouncer" to remove the brakes from the dopamine system. Ultimately, this episode offers profound vindication for patients stuck in the gray zone: anhedonia is not a moral failing or a psychological attitude, but a physical deficit in the brain's wiring that ketamine is structurally capable of repairing. Reference: Faisal, H., Le, G. H., Kwan, A. T. H., Wong, S., Cheung, W., Dri, C. E., Cao, B., Rhee, T. G., Bargiota, S., Lo, H. K. Y., Shen, B., Guillen-Burgos, H. F., & McIntyre, R. S. (2026). Effect of ketamine on reward processing in depressive disorders: A systematic review of neuroimaging studies. CNS Spectrums. https://doi.org/10.1017/S109285292610087X

In Episode 57, we explore a groundbreaking 2026 study out of Hungary by Koncz and colleagues that challenges the foundation of modern psychiatry: do you actually have to "trip" to heal? For years, the pharmaceutical industry has searched for a sanitized, at-home version of ketamine, hoping that R-ketamine (arketamine) could deliver neuroplasticity without the intense psychotomimetic effects of standard S-ketamine (esketamine). By utilizing quantitative EEG (qEEG) signals, researchers discovered the "Gamma-Delta Shift"—the electrical signature of the brain actively rewiring. S-ketamine acts like a controlled forest fire: it triggers a massive, high-frequency "gamma storm" (the trip) which creates a massive cellular energy debt. This debt forces a mandatory "delta rebound" during deep sleep, which is when the actual physical remodeling and synaptic plasticity occur. The shocking twist? Even at four times the normal dose, arketamine completely failed to trigger this shift. This perfectly mirrors its recent failure in human clinical trials, where it did not show a statistically significant antidepressant effect compared to a placebo. The data draws a clear line: you cannot bypass the chaotic exertion phase and still get the structural repair. The altered state isn't a side effect to be engineered away; it is a necessary feature of the cure. Reference: Koncz, S., Pothorszki, D., Papp, N., Pál, D., & Bagdy, G. (2026). Differential effects of ketamine enantiomers on EEG parameters including the gamma-delta shift phenomenon. British Journal of Pharmacology, 1-15. https://doi.org/10.1111/bph.70399

In Episode 56, we explore a fascinating 2026 pharmacokinetics study by Otto and colleagues that completely changes how we view oral ketamine for Treatment-Resistant Depression (TRD). When taken orally, ketamine hits a massive biological roadblock: the liver's "first-pass effect". The liver acts as an aggressive tollbooth, metabolizing almost all of the parent drug and transforming it into a high volume of a metabolite called (S)-norketamine before it reaches the wider bloodstream. Using advanced Pharmacokinetic-Pharmacodynamic (PKPD) modeling, researchers discovered a mind-bending reality. While intravenous ketamine drips rely on the original parent drug to drive the therapeutic high, the subjective experience of an oral pill is almost entirely driven by its metabolite, (S)-norketamine. Because this metabolite is a "clunkier key" with a lower affinity for NMDA receptors, it requires a massive volume to overwhelm the system and produce the necessary psychotomimetic effects. The study's simulations reveal a major clinical hurdle: standard oral doses (like 0.2 or 0.45 mg/kg) fall significantly short of matching the proven therapeutic experience of an IV drip. To achieve those same effects, oral doses must be drastically increased to approximately 1.0 mg/kg. We discuss what this means for the future of TRD treatment, the need for new safety monitoring strategies due to delayed absorption, and the unsettling realization that the pills we swallow aren't always the chemicals that heal us. Reference: Otto, M. E., Jacobs, G. E., van Mechelen, J. C., Borghans, L. G. J. M., van Hasselt, J. G. C., & Aulin, L. B. S. (2026). Pharmacokinetics and pharmacodynamics of intravenous and oral (S)-ketamine: Investigating metabolite contribution to subjective effects. British Journal of Clinical Pharmacology, 1-12. https://doi.org/10.1002/bcp.70503

Bipolar depression creates an agonizing clinical trap: patients are paralyzed by severe lows, yet traditional antidepressants take weeks to work and carry the terrifying risk of an "affective switch"—triggering a manic episode or rapid cycling. In Episode 55, we explore a 2026 review by Queissner and colleagues showing how ketamine and esketamine rewrite the rules by bypassing serotonin and targeting the brain's glutamate "gas pedal". We unpack the staggering data: an odds ratio of 10.68 for rapid relief, with the REAL-ESK study showing zero cases of manic switching in real-world patients using intranasal esketamine. The episode dives deep into the biology, exploring Rizzo's 2025 discovery of ketamine's dual mechanism (NMDA and mu-opioid receptor modulation) that specifically targets anhedonia by restoring dopamine to the brain's reward center. Finally, we discuss why ketamine isn't a solo act—and how foundational mood stabilizers like lithium act as a safety net that synergizes with ketamine to spark central neuroplasticity and structural brain repair. Reference: Queissner, R., Fellendorf, F., & Reininghaus, E. Z. (2026). Ketamine as an NMDA-modulating therapy in bipolar disorder: Rationale and evidence. Frontiers in Psychiatry, 17, 1777402. https://doi.org/10.3389/fpsyt.2026.1777402

For decades, medicine has sold us the comforting "light switch" theory: under general anesthesia, we simply cease to exist for a few hours. But in Episode 54, we unpack Bruno Tonetto’s terrifying and fascinating 2026 paper, "Conscious Under Anesthesia," which argues that we have confused the silence of the body with the absence of the mind. We explore the "broken speaker" analogy, revealing how paralytics trap patients in a silent body, while premedications like Midazolam act as chemical memory wipers (anterograde amnesia) to ensure the experience is forgotten. The most chilling evidence? The Isolated Forearm Technique, where researchers block the paralytic from reaching one arm, revealing that up to a third of paralyzed, "unconscious" patients can squeeze a hand to answer complex questions—yet remember absolutely nothing upon waking. Finally, we tackle the "Ketamine Paradox." As an approved anesthetic that triggers hyper-vivid, mystical experiences, ketamine completely breaks the traditional "production model" of the brain. Instead, Tonetto argues for the "constraint model," suggesting the brain is not a turbine generating consciousness, but a "reducing valve" filtering it. When ketamine unplugs the sensory inputs, the filter breaks, and the mind expands. Reference: Tonetto, B. (2026). Conscious under anesthesia: What the clinical evidence actually shows. Project: Return to Consciousness. https://brunoton.github.io/return-to-consciousness/rtc/ and https://brunoton.github.io/return-to-consciousness/exports/pdf/cua.pdf

In episode 53, we move out of the sterile lab and into the messy real world, examining a large naturalistic study of 224 patients from an Austin clinic. The paper by Kosted and colleagues compares standard "infusion-only" ketamine treatment against Ketamine-Assisted Therapy (KAT) to answer a costly question: is paying for a therapist to be in the room actually worth it? The average results were shocking: across the entire sample, the therapy group didn't fare any better than the infusion-only group. But when researchers sliced the data by age and Adverse Childhood Experiences (ACEs), a much more complex story emerged. We unpack the counterintuitive "super responder" effect, where patients with high childhood trauma saw the most dramatic biological healing. For young adults under 30, the medicine alone was often more effective, suggesting that talk therapy might actually interrupt the "bake" of neuroplasticity by shifting activity to the analytical brain too soon. Conversely, for patients over 50, therapy was essential; without a human connection to help navigate and rewire decades of compensatory behaviors, the ketamine alone often fell short. Finally, we discuss the practical implications of the "decelerating curve" of improvement—where the most dramatic drops in depression occur early in treatment—and why the future of personalized psychiatry must look beyond DNA to a patient's lived biography. Reference: Kosted, R., Waddell, A., Adolph, K., & Fonzo, G. A. (2026). Age-related moderation of adjunctive psychotherapy and early life stress effects on depression symptom reductions following ketamine treatment: Initial insights from a large, naturalistic sample. Journal of Affective Disorders, 402, 121350. https://doi.org/10.1016/j.jad.2026.121350

For the podcast's one-year anniversary, we zoom out from single studies to examine a comprehensive masterpiece: the doctoral thesis of Jolien K.E. Veraart, representing nine years of research (2016–2026) at the University of Groningen. This document moves beyond the initial hype of "does it work?" to the mature, difficult questions of long-term maintenance and safety. We unpack the critical concept of auto-induction—the discovery that the liver eventually "learns" to metabolize ketamine so efficiently that stable doses stop working, creating a bioavailability trap that looks like relapse but is actually just enzymatic efficiency. The episode also tackles the "nightmare" of oral dosing, where absorption is so variable that it makes consistent treatment a roll of the dice. Finally, we discuss the philosophical shift in Veraart’s work: moving away from the "trip" as the cure and toward a model where ketamine simply "softens the clay" of the brain. This places the responsibility back on set and setting not just as a safety measure, but as the tool that sculpts the neuroplastic brain into a healthier shape. Reference: Veraart, J. K. E. (2026). Ketamine for depression: Moving from research to clinical practice [Doctoral thesis, University of Groningen]. https://doi.org/10.33612/diss.1484805904

In the world of ketamine therapy, there is a distinct divide: the FDA-approved, insurance-covered "Gold Standard" (Esketamine/Spravato) versus the cheap, off-label generic (Racemic Ketamine). In this episode, we step into the ring to judge "The Nasal Spray Wars" using a groundbreaking 2026 meta-analysis by Bahji and colleagues published in the Journal of Affective Disorders. We break down the "skim milk vs. whole milk" pharmacology: Esketamine isolates just the S-isomer, while generic ketamine contains both the S and R isomers. Big Pharma argues the isolate is cleaner, but the data tells a different story. We reveal the study's stunning conclusion: there is no significant difference in symptom relief between the two. In fact, the "cheap" generic showed higher remission rates and lower dropout rates than its expensive counterpart. The discussion tackles the massive elephant in the room: accessibility. With Spravato costing thousands of dollars per month and requiring strict in-clinic monitoring, we ask if the "premium" price tag is buying better health or just a patent. We conclude with a verdict for patients paying out-of-pocket: choosing the generic isn't "settling"—it may actually be the more effective, and certainly the more sustainable, path to recovery. Reference: Sarlon, J., Thomi, D., Brühl, A. B., Liwinski, T., & Lang, U. E. (2026). Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study. Journal of Affective Disorders, 400, 121208. https://doi.org/10.1016/j.jad.2024.07.054

For decades, we’ve imagined the synapse as a "chemical soup"—a messy place where one neuron sprays neurotransmitters at another, hoping for a connection. But in this milestone 50th episode, we use the lens of the groundbreaking book Nano-Organization of the Synapse to reveal the stunning reality: the synapse is actually a piece of high-precision Swiss watchmaking. We explore the revolution in super-resolution microscopy (like STORM and cryo-electron tomography) that has allowed us to see the nanocolumn—a dedicated architectural alignment where a presynaptic "launch pad" (controlled by the protein Munc13) sits perfectly opposite a postsynaptic "receiver slot" (held by PSD95). This "trans-synaptic alignment" ensures that every signal is a sniper shot, not a sprinkler spray. The episode dives into the three modes of transmission—synchronous (the fast lane), asynchronous (the stutter), and the critical spontaneous release (the "ghost in the machine"). We discuss the theory that depression is a failure of this nanoscopic geometry, where the "ghost" signal reinforces a broken state. Finally, we explain how ketamine acts as a rapid repair crew: by silencing the spontaneous noise at NMDA receptors, it triggers a panic-like "homeostatic plasticity" that forces the neuron to realign its columns, add more AMPA receptors (volume knobs), and restore the "liquid crystal" dance of the synapse. Reference: Kavalali, E. T. (Ed.). (2026). Nano-organization of the synapse: From structure to function (Vol. 48). Springer Nature Switzerland. https://doi.org/10.1007/978-3-032-12594-1

For decades, the "Monoamine Dogma" ruled psychiatry: the brain was a chemical soup, depression was a lack of serotonin, and the cure was simply "filling the tank." But there was always a glitch in the matrix—why did it take weeks for pills to work if the chemistry changed in hours? In this special 25th-anniversary episode, we review a retrospective paper from 2026 that traces the history of the "Neuroplastic Revolution." We go back to the turning point: the accidental discovery that ketamine could stop depression in four hours, proving the problem wasn't a lack of fuel, but broken wiring. We unpack the science of structural repair: how ketamine blocks the "disappointment center" (the lateral habenula), wakes up the "construction foreman" (mTOR), and releases BDNF (Miracle-Gro for the brain) to physically regrow lost connections. We also look at the macro level, exploring how this "reboot" disrupts the Default Mode Network to stop the loop of rumination. Finally, we discuss where we are today in 2026: the age of Precision Psychiatry, where we stop guessing and start treating the specific biological cause—whether it’s inflammation, glutamate, or connectivity. Reference: Bulek, D., & BaDour, S. (2026). From monoamine deficits to multiscale plasticity: Twenty-five years of ketamine and the neurophysiology of depression. Journal of Neurophysiology. https://doi.org/10.1152/jn.00516.2025

Patients with diabetes often face a brutal "syndemic"—a tangled web of chronic illness, Relentless nerve pain (neuropathy), and severe depression, all fueled by a common biological enemy: metabolic inflammation and Advanced Glycation End-products (AGEs). In this episode, we explore why ketamine, with its rapid antidepressant and non-opioid painkilling properties, looks like the perfect "two birds, one stone" solution on paper. But in practice, it requires walking a high-stakes "metabolic tightrope." We dive into the complex risks: The Glucose Rollercoaster: Ketamine can trigger a stress response that spikes blood sugar (hyperglycemia), yet in Type 1 diabetics, it has also been linked to dangerous, delayed drops (hypoglycemia). The Liver "Traffic Jam": In Type 2 diabetes, fatty liver disease can clog the body's filter, slowing down drug clearance and potentially turning a normal dose toxic. The Metformin Paradox: We discuss preclinical warnings that metformin—the most common diabetes drug—might actually blunt ketamine’s antidepressant effects. The solution? A move away from "one-size-fits-all" medicine toward Model-Informed Precision Dosing—using a patient’s kidney function, liver health, and genetics to calculate the perfect, safe dose. Reference: Sukhram, S. D., Sanchez, M., Anidugbe, A., Kupa, B., Edwards, V. P., Zia, M., & Yilmaz, G. (2026). Ketamine in diabetes care: Metabolic insights and clinical applications. Pharmaceutics, 18(1), 81. https://doi.org/10.3390/pharmaceutics18010081

Clinicians measure success in symptom scores and receptor occupancy, but for patients with Treatment-Resistant Depression (TRD), success is defined by something far more personal: the return of connection, clarity, and "life." In this episode, we amplify the "Patient's Voice" through a comprehensive synthesis of qualitative studies by Walasek and colleagues. We trace the emotional arc of treatment, starting with the profound ambivalence of patients who see ketamine as a "last resort"—terrified it will be just another failure in a long line of disappointments. We then step inside the acute experience itself, often described as a "rollercoaster" where euphoria and panic can flip on a dime, making the safety of the setting and the empathy of the staff critical to preventing trauma. The discussion challenges the medical model's obsession with dissociation as a measurable "active ingredient," revealing that patients value the meaning they make of the experience—the moments of insight and emotional release—far more than the intensity of the "trip" itself. Finally, we expose the hidden barriers to care: the crushing financial burden, the stigma of using a "party drug," and the finding that patients often attribute up to 50% of their therapeutic outcome not to the molecule, but to the kindness and support of the clinical staff.

For decades, the "trip" caused by ketamine—sensory detachment, time warping, and out-of-body experiences—was seen as a nuisance, a "bug" to be tolerated during anesthesia. But a groundbreaking 2025 review paper by Berra and colleagues asks a provocative question: What if dissociation is actually the point? In this episode, we dive into the "Science of Dissociation," exploring the spectrum from simple "checking out" (daydreaming) to profound depersonalization and derealization. We analyze the "switch" in the brain—how ketamine blocks NMDA receptors on inhibitory interneurons, unleashing a glutamate burst that disrupts the Default Mode Network (DMN). This disruption forces the brain into a "chaotic" state of higher entropy, breaking rigid, depressive thought loops and allowing the mind to form new, healthier connections. We also look to the future of "non-hallucinogenic" alternatives like hydroxynorketamine (HNK), which promote neuroplasticity without the trip. This raises a fundamental philosophical and clinical question: Is the conscious experience of an altered state the "price of admission" for healing, or can we bypass the mind to fix the brain? Reference: Bera, K., Looger, L. L., Proekt, A., & Cichon, J. (2025). Cortical mechanisms contributing to ketamine-induced dissociation. The Neuroscientist, 1–17. https://doi.org/10.1177/10738584251403946

For decades, ketamine has been viewed primarily through two lenses: a safe anesthetic or a rapid-acting antidepressant "reset button." But a new paper by Sophie Holland argues we may be missing half the picture. This episode challenges the binary view of ketamine by exploring two distinct therapeutic pathways defined essentially by dose: the Psychedelic and the Psycholytic. The Psychedelic Path (High Dose): We examine the "reset button" model—intense, dissociative experiences driven by a massive glutamatergic burst. The goal here is ego dissolution, allowing patients with severe, treatment-resistant depression or PTSD to emotionally decouple from trauma and achieve rapid symptom reduction. The Psycholytic Path (Low Dose): We contrast this with the "relational tool" model. Here, the goal isn't to leave the body, but to loosen the ego just enough to lower psychological defenses. This trance-like state allows patients to stay connected to their therapist, accessing repressed memories and processing emotions in real-time with less fear. The discussion also tackles the debate over ketamine’s classification—is it truly a psychedelic? While chemically distinct from "classic" psychedelics like psilocybin, its ability to induce neuroplasticity (acting as a psychoplastogen) and non-ordinary states of consciousness places it firmly in the psychedelic therapeutic spectrum. Finally, we look at the physical realities. With chronic high-dose use linked to ulcerative cystitis, does the low-dose psycholytic approach offer a safer, more sustainable model for long-term relational work?. We also touch on the frontier of "betterment of the well," exploring how low-dose protocols might enhance creativity, teamwork, and problem-solving in healthy individuals. Reference: Holland, S. (2025). Ketamine reimagined: Distinguishing psychedelic and psycholytic modalities for next-generation therapies. Silva Wellness. DOI: 10.22541/au.176538434.48451693/v1

Sickle Cell Disease (SCD) pain crises are the leading cause of hospitalization for affected children, causing excruciating vaso-occlusive episodes where misshapen blood cells block oxygen flow to tissues. For decades, the standard treatment has been high-dose opioids, but this often leads to tolerance, inadequate relief, and the dangerous paradox of opioid-induced hyperalgesia—where the treatment actually makes the nervous system more sensitive to pain. In this episode, we analyze a massive cross-sectional study from 44 U.S. children’s hospitals involving over 74,000 admissions. The study asks a critical question: Can ketamine, an NMDA receptor antagonist that "turns down the volume" on central sensitization, break the cycle of pain where opioids fail? The findings reveal a slow but steady rise in ketamine use (doubling from 2.3% in 2016 to 5.7% in 2023), mostly reserved for older children with severe disease markers like chronic pain or hydroxyurea use. But the most stunning insight is about timing. The study found that when ketamine was administered early (within the first 3 days of admission), it cut the median hospital Length of Stay (LOS) in half—from 12 days to just 6 days—and drastically reduced the days patients needed IV opioids. Despite these compelling results, huge gaps in care remain, with some hospitals using ketamine in 20% of cases and others in 0%. We discuss the institutional barriers, stigma, and red tape that prevent clinicians from using this powerful tool when it matters most: early in the crisis. Reference: Jenkins, A. M., Hendry, E., Power-Hays, A., Valentino, M., Hall, M., Kyler, K. E., Antoon, J. W., Tang Girdwood, S., Goldman, J. L., Morel, A. N., Savage, T. J., Orth, L. E., & Archer, N. M. (2025). Increasing ketamine administration in children's hospitals for youth with sickle cell disease. Blood Advances. https://doi.org/10.1182/bloodadvances.2025016826

"Will this actually work for me?" It is the most critical question patients ask before investing time, money, and hope into ketamine therapy. In this episode, we analyze a massive body of research—including a systematic review of 112 studies and a real-world analysis of 77 patients —to find actionable predictors of success. The results are reassuringly broad: factors like age, sex, depression severity, trauma history, and even the intensity of dissociation do not predict whether ketamine will work. However, the data reveals two powerful signals that every patient should know: The "Line in the Sand": The strongest negative predictor is pharmacological resistance. Patients who have failed more than six previous antidepressant trials were significantly less likely to respond to ketamine. The "Perfect" Positive Signal: Researchers identified an early marker of success after just the second infusion. A tiny symptom reduction of just 4.1% on the PHQ-9 scale carried a Positive Predictive Value of 1.0—meaning 100% of patients who hit this mark went on to achieve a clinical response. Crucially, we explain why early non-improvement does not mean failure, as nearly half of patients who showed zero improvement after dose two still achieved a response by the end of treatment. Join us to learn why ketamine might need to be considered earlier in the treatment timeline, before pharmacological resistance sets in. Reference: Syed, O. A. (2025). Predictors of the antidepressant effects of ketamine and psychedelic substances [Master's thesis, University of Toronto]. TSpace Repository.

Surgery is a trauma that wrecks sleep, and for vulnerable patients, Post-Operative Sleep Disturbance (PSD) is a serious complication linked to delirium, increased pain, and slowed recovery. In this episode, we dive into a fascinating study that connects three seemingly unrelated dots: ketamine, sleep, and the oral microbiome. Researchers treated 130 high-risk surgical patients with a continuous low-dose infusion of esketamine. The clinical results were striking: the rate of PSD dropped from 65% in the control group to just 43% in the esketamine group. Patients reported significantly better sleep quality and required far fewer opioids like hydromorphone. But the real surprise was found in their saliva. The study revealed that esketamine treatment actively reshaped the oral microbial community—boosting beneficial bacteria like Streptococcus while suppressing groups like Bacteroidota that were linked to poor sleep. Why would an IV anesthetic change mouth bacteria? We explore the leading theories: Systemic Anti-Inflammation: Surgery floods the body with pro-inflammatory cytokines (a "systemic fire"). Ketamine’s powerful anti-inflammatory properties may calm this environment, making the host less hospitable to stress-related microbes. The Gut-Oral Axis: Ketamine may influence the gut microbiome, with effects rippling up to the mouth to stabilize the body's entire ecosystem. This research challenges us to rethink how psychiatric drugs work—not just by hitting receptors in the brain, but by restoring ecological balance to the nerves, immune system, and the trillions of microbes that live within us. Reference: Li, X.-Y., Qiu, D., Du, N., Hashimoto, K., Wang, X.-M., & Yang, J.-J. (2025). Esketamine prevents postoperative sleep disturbance in patients with preoperative sleep disorders: A role for oral microbiota. Translational Psychiatry, 15(1), 501. https://doi.org/10.1038/s41398-025-03705-9

Catatonia is often misunderstood as simple immobility, but it is a terrifying, life-threatening syndrome of stupor, mutism, and extreme negativism—a state where the brain is essentially "frozen." For decades, the standard protocol has been to step on the "brake pedal" using GABA-ergic drugs like lorazepam, followed by Electroconvulsive Therapy (ECT) if medication fails. But what happens when the brakes don't work, and ECT is medically unsafe or unavailable? This episode analyzes a new systematic review of 10 unique case reports that suggests NMDA receptor antagonists like ketamine and esketamine could be the "skeleton key" for these desperate scenarios. We explore the neurochemistry of switching from the failed inhibitory (GABA) pathway to directly targeting the excitatory (Glutamate) system. The theory? Refractory catatonia may be driven by a massive glutamate hypo-function—the brain's engine isn't firing—and ketamine triggers the necessary surge to reset the circuit. The clinical results discussed are striking: 100% of the patients in the review showed symptom improvement, often within hours to days. We also debunk the common fear that ketamine might destabilize these fragile patients by triggering mania or psychosis; the review found these risks were not supported by the data. Finally, we highlight the practical game-changer of intranasal esketamine, which allows clinicians to bypass the resistance often seen in mute, withdrawn patients who cannot swallow pills. Reference: van der Meer, P. B., Verboeket, S., Slooter, A. J. C., Schoones, J. W., van Noorden, M. S., Somers, M., Batalla, A., & Dols, A. (2025). Treatment with (es)ketamine in catatonia: A systematic review of case reports. The Journal of Clinical Psychiatry, 86(4), Article 25br15940. https://doi.org/10.4088/JCP.25br15940

We move beyond depression and anesthesia to examine ketamine's role in fighting one of the most severe types of chronic pain imaginable: Complex Regional Pain Syndrome (CRPS). This condition is marked by wildly disproportionate and persistent pain , exemplified by the case of a 15-year-old athlete whose simple hand fracture healed, but whose nervous system got stuck in a pathological pain loop. The core problem in CRPS is central sensitization—the brain and spinal cord jamming the "volume knob" for pain on maximum, where a light touch (allodynia) is interpreted as excruciating. Traditional treatments fail because the problem is upstream, residing in the central nervous system (CNS). Specialists employed a clever, multimodal strategy to finally break this refractory pain cycle: Gabapentin: To calm general static in the nervous system. Continuous Nerve Block: A regional anesthetic to temporarily silence all incoming peripheral pain signals from the arm. Continuous Ketamine Infusion: The NMDA receptor antagonist was the core component, performing a "software reboot" on the CNS. Ketamine acts as a master switch, physically blocking the NMDA receptor that powers the central sensitization system, thereby interrupting the vicious wind-up cycle. The results were dramatic: pain, which was agonizing, dropped from 7/10 to 2/10 within 24 hours, resolving completely in 48 hours. Allodynia resolved, enabling the essential physiotherapy needed for long-term recovery. This case report is a powerful demonstration of ketamine's versatility, showing it can act not just as a painkiller, but as a system reset for neurological conditions rooted in faulty learning. Reference: Medikondu, H., Davit, A., & Visoiu, M. (2025). Effective Adolescent Hand CRPS Type 1 Treatment Using Ketamine, Gabapentin, and Supraclavicular Nerve Block Catheter. Preprints.org. https://doi.org/10.20944/preprints202511.0755.v1